Express News | Kexon Biotech: KeyVac won the bid for Turkey's long-term supply project for hepatitis A and chickenpox vaccines
Sinovac Biotech Embraces Post-Pandemic Challenges
Sinovac Biotech 2H Sales $307.9 >SVA
Sinovac Biotech 2H Sales $307.9 >SVA
Express News | Investing in Xingmeng Biotech, Kexon Biotech enters a new field of innovative antibody drugs
Seasonal Influenza Global Clinical Trials Review 2024 Featuring GSK, Novartis, Johnson & Johnson, Novavax, CSL, Sinovac Biotech, Moderna, and Sanofi, Among Others
Sernova Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
Express News | Kexon Biotech: Clinical Study on Adsorbed Tetanus Vaccine Reveals Mysteries
Express News | Kexon Biotech's Board of Directors Advises Shareholders to Reject Alternative Liquidity's Offer to Acquire
SINOVAC Updates on the Clinical Trial Progress of Its Anti-COVID-19 Antibody SA55 Injection
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
Sinovac: Given Ongoing Litigation Concerning Exchange of Shares & Rights Agreement, Unclear If or When Halt Will Lift >SVA
Sinovac: Given Ongoing Litigation Concerning Exchange of Shares & Rights Agreement, Unclear If or When Halt Will Lift >SVA
Sinovac Is a China-based Biopharma Co With Vaccine Portfolio Including Covid, Hep A >SVA
Sinovac Is a China-based Biopharma Co With Vaccine Portfolio Including Covid, Hep A >SVA
Sinovac: Board Also Considered Other Material Risks >SVA
Sinovac: Board Also Considered Other Material Risks >SVA
Sinovac: Also Has $9.4B in Short-Term Investments, Posted 1H $14.0M in Net Income >SVA
Sinovac: Also Has $9.4B in Short-Term Investments, Posted 1H $14.0M in Net Income >SVA
Sinovac: This Suggests Lack of Credibility in Alternative Liquidity's Valuation >SVA
Sinovac: This Suggests Lack of Credibility in Alternative Liquidity's Valuation >SVA
Sinovac: Alternative Liquidity Said It Didn't Have Accurate Means for Determining Shares' Value >SVA
Sinovac: Alternative Liquidity Said It Didn't Have Accurate Means for Determining Shares' Value >SVA
Sinovac: Cash Position of $1.6B as of End June Represents $14.40/Share >SVA
Sinovac: Cash Position of $1.6B as of End June Represents $14.40/Share >SVA
Sinovac: Offer's Implied Valuation Is Less Than Company's Assets Value >SVA
Sinovac: Offer's Implied Valuation Is Less Than Company's Assets Value >SVA
Sinovac Board Says Offer Not Advisable or in Best Interests of Company, Shareholders >SVA
Sinovac Board Says Offer Not Advisable or in Best Interests of Company, Shareholders >SVA
Alternative Liquidity Had Made Cash Offer for Up to 10M Common Sinovac Shares for $0.03 Each >SVA
Alternative Liquidity Had Made Cash Offer for Up to 10M Common Sinovac Shares for $0.03 Each >SVA
Sinovac Board Unanimously Rejects Unsolicited Partial Tender Offer From Alternative Liquidity Index LP >SVA
Sinovac Board Unanimously Rejects Unsolicited Partial Tender Offer From Alternative Liquidity Index LP >SVA
No Data